European Equities Traded in US as ADRs Advance in Tuesday Trading

MT Newswires Live08-04 23:06

European equities traded in the US as American depositary receipts rose late Tuesday morning with the S&P Europe Select ADR Index gaining 0.6% to 1,941.81.

From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and medical device maker EDAP TMS (FOCL), which climbed 11% and 5.3%, respectively. They were followed by telecommunications company Nokia (NOK) and internet ad firm Criteo (CRTO), which advanced 5.2% and 3.2%, respectively.

The decliners from continental Europe were led by petroleum refiner Equinor (EQNR) and oil and gas company Eni (E), which fell 2.1% and 1.8%, respectively. They were followed by accommodations platform trivago (TRVG) and pharmaceutical company Ascendis Pharma (ASND), which were down 0.9% each.

The gainers from the UK were led by mining company BHP Group (BHP) and pharmaceutical company Silence Therapeutics (SLN), which rose 3.8% and 3%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and lender Barclays (BCS), which were up 2.5% and 1.3%, respectively.

The decliners from the UK and Ireland were led by medical device maker Smith & Nephew (SNN) and oil and gas company BP (BP), which dropped 5.8% and 4%, respectively. They were followed by educational publisher Pearson (PSO) and oil and gas company Shell (SHEL), which lost 1.6% and 1.4%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment